{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:54:37Z","timestamp":1788026077137,"version":"build-2784847793"},"reference-count":194,"publisher":"Bioscientifica","issue":"6","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:p>Tumourigenesis is a relatively common event in endocrine tissues. Currently, specific guidelines have been developed for common malignant endocrine tumours, which also incorporate advances in molecular targeted therapies (MTT), as in thyroid cancer and in gastrointestinal neuroendocrine malignancies. However, there is little information regarding the role and efficacy of MTT in the relatively rare malignant endocrine tumours mainly involving the adrenal medulla, adrenal cortex, pituitary, and parathyroid glands. Due to the rarity of these tumours and the lack of prospective studies, current guidelines are mostly based on retrospective data derived from surgical, locoregional and ablative therapies, and studies with systemic chemotherapy. In addition, in many of these malignancies the prognosis remains poor with individual patients responding differently to currently available treatments, necessitating the development of new personalised therapeutic strategies. Recently, major advances in the molecular understanding of endocrine tumours based on genomic, epigenomic, and transcriptome analysis have emerged, resulting in new insights into their pathogenesis and molecular pathology. This in turn has led to the use of novel MTTs in increasing numbers of patients. In this review, we aim to present currently existing and evolving data using MTT in the treatment of adrenal, pituitary and malignant parathyroid tumours, and explore the current utility and effectiveness of such therapies and their future evolution.<\/jats:p>","DOI":"10.1530\/erc-16-0542","type":"journal-article","created":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T20:40:27Z","timestamp":1491943227000},"page":"R239-R259","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":17,"title":["Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies"],"prefix":"10.1530","volume":"24","author":[{"given":"Anna","family":"Angelousi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios K","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Zografos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"N\u00f6lting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Kaltsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"2017052317102927000_24.6.R239.1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12253-011-9483-7","article-title":"Molecular profiling of parathyroid hyperplasia, adenoma and carcinoma","volume":"18","author":"Arvai","year":"2012","journal-title":"Pathology and Oncology Research"},{"key":"2017052317102927000_24.6.R239.2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2953"},{"key":"2017052317102927000_24.6.R239.3","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2953"},{"key":"2017052317102927000_24.6.R239.4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"15","author":"Averbuch","year":"1988","journal-title":"Annals of Internal Medicine"},{"key":"2017052317102927000_24.6.R239.5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1946"},{"key":"2017052317102927000_24.6.R239.6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2356"},{"key":"2017052317102927000_24.6.R239.7","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"key":"2017052317102927000_24.6.R239.8","doi-asserted-by":"crossref","unstructured":"Aung Naing SF Habra MA Chugh R Kebebew E Russell J Welshans D Fassnacht M Kroiss M Goebeler ME Ijzerman M 2015 ATR-101 phase 1 clinical study for adrenocortical carcinoma. Journal of Clinical Oncology 33 (15 suppl) abstract TPS4585. (available at: http:\/\/ascopubs.org\/doi\/abs\/10.1200\/jco.2015.33.15_suppl.tps4585)","DOI":"10.1200\/jco.2015.33.15_suppl.tps4585"},{"key":"2017052317102927000_24.6.R239.9","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0373-5"},{"key":"2017052317102927000_24.6.R239.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0132"},{"key":"2017052317102927000_24.6.R239.11","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2013.775293"},{"key":"2017052317102927000_24.6.R239.12","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0918"},{"key":"2017052317102927000_24.6.R239.13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/annonc\/mds231","article-title":"Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Berruti","year":"2012","journal-title":"Annals of Oncology"},{"key":"2017052317102927000_24.6.R239.14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031911"},{"key":"2017052317102927000_24.6.R239.15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1055\/s-0030-1253419","article-title":"SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases","volume":"118","author":"Bode","year":"2010","journal-title":"Experimental and Clinical Endocrinology and Diabetes"},{"key":"2017052317102927000_24.6.R239.16","first-page":"271","article-title":"Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer","volume":"39","author":"Brave","year":"2011","journal-title":"International Journal of Oncology"},{"key":"2017052317102927000_24.6.R239.17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/ERC-11-0231","article-title":"The role of fibroblast growth factor receptor 4 overexpression and gene amplification as prognostic markers in pediatric and adult adrenocortical tumors","volume":"19","author":"Brito","year":"2012","journal-title":"Endocrine-Related Cancer"},{"key":"2017052317102927000_24.6.R239.18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1346"},{"key":"2017052317102927000_24.6.R239.19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40169-015-0080-3","article-title":"Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma","volume":"5","author":"Bussey","year":"2016","journal-title":"Clinical and Translation Medicine"},{"key":"2017052317102927000_24.6.R239.20","doi-asserted-by":"publisher","DOI":"10.1517\/14728220903170675"},{"key":"2017052317102927000_24.6.R239.21","doi-asserted-by":"publisher","DOI":"10.1038\/ng1048"},{"key":"2017052317102927000_24.6.R239.22","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/modpathol.2013.233","article-title":"Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas","volume":"27","author":"Cassol","year":"2014","journal-title":"Modern Pathology"},{"key":"2017052317102927000_24.6.R239.23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2951"},{"key":"2017052317102927000_24.6.R239.24","doi-asserted-by":"publisher","DOI":"10.1159\/000371806"},{"key":"2017052317102927000_24.6.R239.25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"2017052317102927000_24.6.R239.26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature19795","article-title":"On-target efficacy of a HIF-2\u03b1 antagonist in preclinical kidney cancer models","volume":"539","author":"Cho","year":"2016","journal-title":"Nature"},{"key":"2017052317102927000_24.6.R239.27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2480"},{"key":"2017052317102927000_24.6.R239.28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1530\/ERC-11-0066","article-title":"Expression and function of ErbB receptors and ligands in the pituitary","volume":"18","author":"Cooper","year":"2011","journal-title":"Endocrine-Related Cancer"},{"key":"2017052317102927000_24.6.R239.29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1530\/ERC-15-0452","article-title":"Future directions in the diagnosis and medical treatment of adrenocortical carcinoma","volume":"23","author":"Creemers","year":"2016","journal-title":"Endocrine-Related Cancer"},{"key":"2017052317102927000_24.6.R239.30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1371\/journal.pgen.0010008","article-title":"A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas","volume":"1","author":"Dahia","year":"2005","journal-title":"PLoS Genetics"},{"key":"2017052317102927000_24.6.R239.31","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3648"},{"key":"2017052317102927000_24.6.R239.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2011.10.006"},{"key":"2017052317102927000_24.6.R239.33","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0112"},{"key":"2017052317102927000_24.6.R239.34","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12020-015-0818-0","article-title":"Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells","volume":"52","author":"De Martino","year":"2016","journal-title":"Endocrine"},{"key":"2017052317102927000_24.6.R239.35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10143-016-0740-9","article-title":"Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients","volume":"40","author":"Del Basso De Caro","year":"2016","journal-title":"Neurosurgical Review"},{"key":"2017052317102927000_24.6.R239.36","doi-asserted-by":"publisher","DOI":"10.1210\/me.2007-0120"},{"key":"2017052317102927000_24.6.R239.37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2163"},{"key":"2017052317102927000_24.6.R239.38","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3970"},{"key":"2017052317102927000_24.6.R239.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2012.07.025"},{"key":"2017052317102927000_24.6.R239.40","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1220687"},{"key":"2017052317102927000_24.6.R239.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2011.02621.x"},{"key":"2017052317102927000_24.6.R239.42","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M609768200"},{"key":"2017052317102927000_24.6.R239.43","doi-asserted-by":"crossref","first-page":"140051","DOI":"10.1530\/EDM-14-0051","article-title":"Catecholamine-secreting carotid body paraganglioma: successful preoperative control of hypertension and clinical symptoms using high-dose long-acting octreotide","volume":"2014","author":"Elshafie","year":"2014","journal-title":"Endocrinology, Diabetes and Metabolism Case Reports"},{"key":"2017052317102927000_24.6.R239.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.11.012"},{"key":"2017052317102927000_24.6.R239.45","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20412"},{"key":"2017052317102927000_24.6.R239.46","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0100323"},{"key":"2017052317102927000_24.6.R239.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200966"},{"key":"2017052317102927000_24.6.R239.48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70081-1"},{"key":"2017052317102927000_24.6.R239.49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors","volume":"175","author":"Fassnacht","year":"2016","journal-title":"European Journal of Endocrinology"},{"key":"2017052317102927000_24.6.R239.50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nature Reviews Endocrinology"},{"key":"2017052317102927000_24.6.R239.51","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"2017052317102927000_24.6.R239.52","doi-asserted-by":"crossref","first-page":"e97712","DOI":"10.1371\/journal.pone.0097712","article-title":"Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells","volume":"9","author":"Fliedner","year":"2014","journal-title":"PLoS ONE"},{"key":"2017052317102927000_24.6.R239.53","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-013-9878-1"},{"key":"2017052317102927000_24.6.R239.54","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60417"},{"key":"2017052317102927000_24.6.R239.55","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bcp.2015.10.012","article-title":"Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors","volume":"98","author":"Gagliano","year":"2015","journal-title":"Biochemical Pharmacology"},{"key":"2017052317102927000_24.6.R239.56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199305063281805"},{"key":"2017052317102927000_24.6.R239.57","doi-asserted-by":"publisher","DOI":"10.1210\/en.2012-1854"},{"key":"2017052317102927000_24.6.R239.58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056083"},{"key":"2017052317102927000_24.6.R239.59","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.clon.2010.04.007","article-title":"Parathyroid carcinoma","volume":"22","author":"Givi","year":"2010","journal-title":"Clinical Oncology"},{"key":"2017052317102927000_24.6.R239.60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3496"},{"key":"2017052317102927000_24.6.R239.61","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0206"},{"key":"2017052317102927000_24.6.R239.62","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01124"},{"key":"2017052317102927000_24.6.R239.63","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28913"},{"key":"2017052317102927000_24.6.R239.64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.9380"},{"key":"2017052317102927000_24.6.R239.65","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/1471-2407-14-561","article-title":"A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers","volume":"14","author":"Halperin","year":"2014","journal-title":"BMC Cancer"},{"key":"2017052317102927000_24.6.R239.66","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1083-9"},{"key":"2017052317102927000_24.6.R239.67","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1440-1754.2002.00802.x","article-title":"Familial parathyroid carcinoma in a child","volume":"8","author":"Hamill","year":"2002","journal-title":"Journal of Paediatrics and Child Health"},{"key":"2017052317102927000_24.6.R239.68","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1212704"},{"key":"2017052317102927000_24.6.R239.69","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0020"},{"key":"2017052317102927000_24.6.R239.70","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2031"},{"key":"2017052317102927000_24.6.R239.71","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2031"},{"key":"2017052317102927000_24.6.R239.72","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K09E-283"},{"key":"2017052317102927000_24.6.R239.73","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-2063-1"},{"key":"2017052317102927000_24.6.R239.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2007.12.440"},{"key":"2017052317102927000_24.6.R239.75","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-12-0403"},{"key":"2017052317102927000_24.6.R239.76","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.mce.2015.09.031","article-title":"Amphiregulin lacks an essential role for the bone anabolic action of parathyroid hormone","volume":"417","author":"Jay","year":"2015","journal-title":"Molecular and Cellular Endocrinology"},{"key":"2017052317102927000_24.6.R239.77","doi-asserted-by":"crossref","unstructured":"Jes\u00fas Garc\u00eda-Donas SHP Guix M Duran MAC M\u00e9ndez- Vidal MJ Jim\u00e9nez-Fonseca P La\u00ednez N Mateos LL Moreno F Gonzalez ERS Duran I 2014 Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011\u201303. Journal of Clinical Oncology 32 (5 Suppl) abstract 4588.","DOI":"10.1200\/jco.2014.32.15_suppl.4588"},{"key":"2017052317102927000_24.6.R239.78","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11060-011-0792-1","article-title":"Analysis of differential gene expression in plurihormonal pituitary adenomas using bead-based fiber-optic arrays","volume":"108","author":"Jiang","year":"2012","journal-title":"Journal of Neurooncology"},{"key":"2017052317102927000_24.6.R239.79","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1972"},{"key":"2017052317102927000_24.6.R239.80","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt201"},{"key":"2017052317102927000_24.6.R239.81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0265"},{"key":"2017052317102927000_24.6.R239.82","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11102-011-0341-0","article-title":"New targeted therapies in pituitary carcinoma resistant to temozolomide","volume":"15","author":"Jouanneau","year":"2012","journal-title":"Pituitary"},{"key":"2017052317102927000_24.6.R239.83","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01058"},{"key":"2017052317102927000_24.6.R239.84","first-page":"481","article-title":"Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas","volume":"34","author":"Juhlin","year":"2009","journal-title":"International Journal of Oncology"},{"key":"2017052317102927000_24.6.R239.85","doi-asserted-by":"publisher","DOI":"10.1126\/science.1135901"},{"key":"2017052317102927000_24.6.R239.86","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2231"},{"key":"2017052317102927000_24.6.R239.87","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01116"},{"key":"2017052317102927000_24.6.R239.88","doi-asserted-by":"crossref","unstructured":"Kantorovich V Koch CA Pacak K 2015 Pheochromocytoma and paraganglioma. In Endotext. Eds: De Groot LJ Chrousos G Dungan K. South Dartmouth, MA, USA: MDText.com, Inc. (available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279138\/)","DOI":"10.1016\/B978-0-12-801238-3.03749-1"},{"key":"2017052317102927000_24.6.R239.89","doi-asserted-by":"publisher","DOI":"10.1080\/00313020410001671957"},{"key":"2017052317102927000_24.6.R239.90","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0166"},{"key":"2017052317102927000_24.6.R239.91","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2053"},{"key":"2017052317102927000_24.6.R239.92","doi-asserted-by":"crossref","first-page":"e0147682","DOI":"10.1371\/journal.pone.0147682","article-title":"Targeting the mTOR complex by everolimus in NRAS mutant neuroblastoma","volume":"11","author":"Kiessling","year":"2016","journal-title":"PLoS ONE"},{"key":"2017052317102927000_24.6.R239.93","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4132\/jptm.2016.06.30","article-title":"The predictive value of pathologic features in pituitary adenoma and correlation with pituitary adenoma recurrence","volume":"50","author":"Kim","year":"2016","journal-title":"Journal of Pathology and Translational Medicine"},{"key":"2017052317102927000_24.6.R239.94","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11102-013-0494-0","article-title":"Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma","volume":"17","author":"Komor","year":"2014","journal-title":"Pituitary"},{"key":"2017052317102927000_24.6.R239.95","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-07-0267"},{"key":"2017052317102927000_24.6.R239.96","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1419"},{"key":"2017052317102927000_24.6.R239.97","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6046"},{"key":"2017052317102927000_24.6.R239.98","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0068"},{"key":"2017052317102927000_24.6.R239.99","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67139-5"},{"key":"2017052317102927000_24.6.R239.100","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1498"},{"key":"2017052317102927000_24.6.R239.101","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12672-014-0182-1","article-title":"The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/ metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial","volume":"5","author":"Lerario","year":"2014","journal-title":"Hormones and Cancer"},{"key":"2017052317102927000_24.6.R239.102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2085"},{"key":"2017052317102927000_24.6.R239.103","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2012.08.035"},{"key":"2017052317102927000_24.6.R239.104","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2926"},{"key":"2017052317102927000_24.6.R239.105","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2012.08.035"},{"key":"2017052317102927000_24.6.R239.106","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2926"},{"key":"2017052317102927000_24.6.R239.107","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.449"},{"key":"2017052317102927000_24.6.R239.108","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-0629"},{"key":"2017052317102927000_24.6.R239.109","unstructured":"Lourenco DE Jr Hoff AO Alcantara AEE Martins RM Correa PHS Menezes M 2012 Radiofrequency ablation of pulmonary metastases in parathyroid carcinoma: an alternative therapy for severe refractory hypercalcemia. Presentation OR27-5. Presented at The Endocrine Society\u2019s 94th Annual Meeting and Expo, June 23\u201326, 2012, Houston, TX. Washington DC, USA: Endocrine Society. (available at: http:\/\/press.endocrine.org\/doi\/abs\/10.1210\/endo-meetings.2012.BCHVD.7.OR27-5)"},{"key":"2017052317102927000_24.6.R239.110","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2015.20"},{"key":"2017052317102927000_24.6.R239.111","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s11102-013-0540-y","article-title":"Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma\/carcinoma: variable clinical response in preliminary evaluation","volume":"17","author":"Maclean","year":"2014","journal-title":"Pituitary"},{"key":"2017052317102927000_24.6.R239.112","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0337"},{"key":"2017052317102927000_24.6.R239.113","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1371\/journal.pone.0014678","article-title":"Pharmacologic modulation of serine\/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy","volume":"6","author":"Martiniova","year":"2011","journal-title":"PLoS ONE"},{"key":"2017052317102927000_24.6.R239.114","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/ki.2010.501","article-title":"The secretory response of parathyroid hormone to acute hypocalcemia in vivo is independent of parathyroid glandular sodium\/potassium-ATPase activity","volume":"79","author":"Martuseviciene","year":"2011","journal-title":"Kidney International"},{"key":"2017052317102927000_24.6.R239.115","first-page":"329","article-title":"Parathyroid cancer","volume":"4","author":"McClenaghan","year":"2015","journal-title":"Gland Surgery"},{"key":"2017052317102927000_24.6.R239.116","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03487.x"},{"key":"2017052317102927000_24.6.R239.117","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2011.02520.x"},{"key":"2017052317102927000_24.6.R239.118","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2006.10.001"},{"key":"2017052317102927000_24.6.R239.119","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2006.10.001"},{"key":"2017052317102927000_24.6.R239.120","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2000.tb04358.x"},{"key":"2017052317102927000_24.6.R239.121","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200320401"},{"key":"2017052317102927000_24.6.R239.122","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4081\/oncol.2014.249","article-title":"Target therapy in metastatic pheochromocytoma: current perspectives and controversies","volume":"8","author":"Mohammed","year":"2014","journal-title":"Oncology Reviews"},{"key":"2017052317102927000_24.6.R239.123","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E05-06-0560"},{"key":"2017052317102927000_24.6.R239.124","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.hoc.2012.08.009","article-title":"Parathyroid carcinoma: challenges in diagnosis and treatment","volume":"26","author":"Mohebati","year":"2012","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"2017052317102927000_24.6.R239.125","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.01.053"},{"key":"2017052317102927000_24.6.R239.126","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01309.x"},{"key":"2017052317102927000_24.6.R239.127","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-010-9592-y"},{"key":"2017052317102927000_24.6.R239.128","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.00949"},{"key":"2017052317102927000_24.6.R239.129","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mce.2010.03.017","article-title":"Cyclins and their related proteins in pituitary tumourigenesis","volume":"326","author":"Mu\u015fat","year":"2010","journal-title":"Molecular and Cellular Endocrinology"},{"key":"2017052317102927000_24.6.R239.130","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2979"},{"key":"2017052317102927000_24.6.R239.131","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.46"},{"key":"2017052317102927000_24.6.R239.132","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12542"},{"key":"2017052317102927000_24.6.R239.133","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-012-9199-6"},{"key":"2017052317102927000_24.6.R239.134","doi-asserted-by":"publisher","DOI":"10.1530\/JME-12-0028"},{"key":"2017052317102927000_24.6.R239.135","doi-asserted-by":"publisher","DOI":"10.1210\/en.2014-1027"},{"key":"2017052317102927000_24.6.R239.136","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27675"},{"key":"2017052317102927000_24.6.R239.137","doi-asserted-by":"crossref","first-page":"e1003975","DOI":"10.1371\/journal.pgen.1003975","article-title":"Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion","volume":"9","author":"Olauson","year":"2013","journal-title":"PLoS Genetics"},{"key":"2017052317102927000_24.6.R239.138","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2925"},{"key":"2017052317102927000_24.6.R239.139","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0346-8"},{"key":"2017052317102927000_24.6.R239.140","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2298"},{"key":"2017052317102927000_24.6.R239.141","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2091-3"},{"key":"2017052317102927000_24.6.R239.142","doi-asserted-by":"publisher","DOI":"10.1159\/000443167"},{"key":"2017052317102927000_24.6.R239.143","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2536"},{"key":"2017052317102927000_24.6.R239.144","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3029-2"},{"key":"2017052317102927000_24.6.R239.145","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2564"},{"key":"2017052317102927000_24.6.R239.146","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0644"},{"key":"2017052317102927000_24.6.R239.147","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04381.x"},{"key":"2017052317102927000_24.6.R239.148","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3166"},{"key":"2017052317102927000_24.6.R239.149","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2011.09.042"},{"key":"2017052317102927000_24.6.R239.150","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/j.1349-7006.2007.00568.x","article-title":"Involvement of cyclooxygenase-2 in the tumor site-dependent production of parathyroid hormone-related protein in colon 26 carcinoma","volume":"98","author":"Saito","year":"2007","journal-title":"Cancer Science"},{"key":"2017052317102927000_24.6.R239.151","first-page":"615","article-title":"Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2\/Akt\/mTOR\/S6K1 pathways through modulation of Bcl-2 and BAD","volume":"302","author":"Saito","year":"2012","journal-title":"American Journal of Physiology: Endocrinology and Metabolism"},{"key":"2017052317102927000_24.6.R239.152","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/jc.2010-0653","article-title":"High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors","volume":"95","author":"Sbiera","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2017052317102927000_24.6.R239.153","doi-asserted-by":"crossref","first-page":"517e524","DOI":"10.1016\/j.tem.2009.06.008","article-title":"The EGFR network in bone biology and pathology","volume":"20","author":"Schneider","year":"2009","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"2017052317102927000_24.6.R239.154","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.drudis.2007.08.006","article-title":"Evaluation of HIF-1 inhibitors as anticancer agents","volume":"20","author":"Semenza","year":"2007","journal-title":"Drug Discovery Today"},{"key":"2017052317102927000_24.6.R239.155","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"NETTER-1 trial investigators. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"2017052317102927000_24.6.R239.156","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.surg.2015.08.023","article-title":"Synthetic high-density lipoprotein nanoparticles: a novel therapeutic strategy for adrenocortical carcinomas","volume":"159","author":"Subramanian","year":"2016","journal-title":"Surgery"},{"key":"2017052317102927000_24.6.R239.157","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.2009.292"},{"key":"2017052317102927000_24.6.R239.158","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.365"},{"key":"2017052317102927000_24.6.R239.159","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2003.07.036"},{"key":"2017052317102927000_24.6.R239.160","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.prp.2010.01.007","article-title":"Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma","volume":"206","author":"Tavangar","year":"2010","journal-title":"Pathology-Research Practice"},{"key":"2017052317102927000_24.6.R239.161","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063360"},{"key":"2017052317102927000_24.6.R239.162","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-009-0211-1"},{"key":"2017052317102927000_24.6.R239.163","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.1158\/0008-5472.CAN-05-0593","article-title":"Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors","volume":"65","author":"Tissier","year":"2005","journal-title":"Cancer Research"},{"key":"2017052317102927000_24.6.R239.164","doi-asserted-by":"publisher","DOI":"10.1038\/nature05315"},{"key":"2017052317102927000_24.6.R239.165","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2508"},{"key":"2017052317102927000_24.6.R239.166","doi-asserted-by":"publisher","DOI":"10.1186\/1478-1336-1-8"},{"key":"2017052317102927000_24.6.R239.167","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"Journal of Nuclear Medicine"},{"key":"2017052317102927000_24.6.R239.168","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/hed.23348","article-title":"Effects of octreotide therapy in progressive head and neck paragangliomas: case series","volume":"35","author":"Van Hulsteijn","year":"2013","journal-title":"Head Neck"},{"key":"2017052317102927000_24.6.R239.169","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12341"},{"key":"2017052317102927000_24.6.R239.170","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-12-0217"},{"key":"2017052317102927000_24.6.R239.171","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111635200"},{"key":"2017052317102927000_24.6.R239.172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2775"},{"key":"2017052317102927000_24.6.R239.173","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0292"},{"key":"2017052317102927000_24.6.R239.174","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0508"},{"key":"2017052317102927000_24.6.R239.175","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3171\/2015.6.JNS15363","article-title":"Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: case report","volume":"125","author":"Walig\u00f3rska-Stachura","year":"2016","journal-title":"Journal of Neurosurgery"},{"key":"2017052317102927000_24.6.R239.176","first-page":"686","article-title":"Clinicopathologic features and expression of epidermal growth factor receptor and vascular endothelial growth factor in adrenocortical tumors","volume":"41","author":"Wang","year":"2012","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"2017052317102927000_24.6.R239.177","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-011-0171-3"},{"key":"2017052317102927000_24.6.R239.178","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3767"},{"key":"2017052317102927000_24.6.R239.179","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamasurg.2016.2310","article-title":"The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism","volume":"151","author":"Wilhelm","year":"2016","journal-title":"JAMA Surgery"},{"key":"2017052317102927000_24.6.R239.180","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0804"},{"key":"2017052317102927000_24.6.R239.181","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-011-9502-1"},{"key":"2017052317102927000_24.6.R239.182","doi-asserted-by":"crossref","first-page":"36235","DOI":"10.18632\/oncotarget.8827","article-title":"Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"2017052317102927000_24.6.R239.183","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-014-1205-7"},{"key":"2017052317102927000_24.6.R239.184","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF03401377","article-title":"The role of Notch and Hedgehog signaling pathways in pituitary development and pathogenesis of pituitary adenomas","volume":"14","author":"Yavropoulou","year":"2015","journal-title":"Hormones"},{"key":"2017052317102927000_24.6.R239.185","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4022"},{"key":"2017052317102927000_24.6.R239.186","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ14-0211"},{"key":"2017052317102927000_24.6.R239.187","doi-asserted-by":"publisher","DOI":"10.3171\/2010.8.JNS10290"},{"key":"2017052317102927000_24.6.R239.188","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1641"},{"key":"2017052317102927000_24.6.R239.189","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4158\/EP.15.5.450","article-title":"American association of clinical endocrinologists. American association of endocrine surgeons. American association of clinical endocrinologists and American association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas: executive summary of recommendations","volume":"15","author":"Zeiger","year":"2009","journal-title":"Endocrine Practice"},{"key":"2017052317102927000_24.6.R239.190","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1007\/s13277-015-3187-7","article-title":"Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma","volume":"36","author":"Zhang","year":"2015","journal-title":"Tumour Biology"},{"key":"2017052317102927000_24.6.R239.191","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0907843106"},{"key":"2017052317102927000_24.6.R239.192","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2002.128613"},{"key":"2017052317102927000_24.6.R239.193","first-page":"196","article-title":"Laparoscopic surgery for malignant adrenal tumors","volume":"13","author":"Zografos","year":"2009","journal-title":"Journal of the Society of Laparoendoscopic Surgeons"},{"key":"2017052317102927000_24.6.R239.194","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1311637"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/24\/6\/R239.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1530\/ERC-16-0542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:54:05Z","timestamp":1784555645000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/24\/6\/R239-R259\/34110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":194,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1530\/erc-16-0542","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}